title: Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
authors.affiliation: 1] Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia [2] Department of Genetics & Pathology & Centre for Cancer Biology, Adelaide, South Australia, Australia [3] Department of Haematology, SA Pathology, Adelaide, South Australia, Australia.
authors.forename: D T
authors.initials: DT
authors.lastname: Yeung
authors.affiliation: 1] Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia [2] Department of Haematology, SA Pathology, Adelaide, South Australia, Australia [3] South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia.
authors.forename: D J
authors.initials: DJ
authors.lastname: Moulton
authors.affiliation: South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia.
authors.forename: S L
authors.initials: SL
authors.lastname: Heatley
authors.affiliation: South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia.
authors.forename: E
authors.initials: E
authors.lastname: Nievergall
authors.affiliation: South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Dang
authors.affiliation: Department of Genetics & Pathology & Centre for Cancer Biology, Adelaide, South Australia, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Braley
authors.affiliation: Department of Genetics & Pathology & Centre for Cancer Biology, Adelaide, South Australia, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Branford
authors.affiliation: Department of Genetics & Pathology & Centre for Cancer Biology, Adelaide, South Australia, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Moore
authors.affiliation: 1] Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia [2] South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia [3] St Jude Children's Research Hospital, Memphis, TN, USA.
authors.forename: C G
authors.initials: CG
authors.lastname: Mullighan
authors.affiliation: 1] Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia [2] Department of Haematology, SA Pathology, Adelaide, South Australia, Australia [3] South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia.
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
authors.affiliation: 1] Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia [2] South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia [3] Discipline of Paediatrics, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
authors.forename: D L
authors.initials: DL
authors.lastname: White
mesh_terms: D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D009154:Mutation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: C581634:BCR-ABL1 fusion protein, human; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011494:Protein Kinases; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib